The latest issue of CAM illustrates how medical researchers have opted for talk, not action, over concerns that drug company funding is influencing the results of clinical trials.
Leaders of the international Cochrane Collaboration, which produces systematic reviews of evidence, decided at its annual conference to consult its 10,000 members rather than address the issue. Cochranes supporters "are deeply divided over how to manage their relationships with private companies, particularly drug manufacturers", reports the British Medical Journal. "Pointing to the well established and favourable outcomes, some people within the collaboration want a prohibition on reviews funded by industry. Others argue that such funding is critical to the groups survival, particularly in countries where state support is lacking."